CEO Interview NYU Sept 2020 - Acrobat pdf 195k 11 September 2020 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: $25m NYU Langone contract Multi-year Research Collaboration Agreement PME to establish R&D hub in New York City Update on pipeline
11 September 2020; Company Announcement NYU Research Collaboration Sept 2020 - Acrobat pdf 114k Highlights PME signs multi-year Research Collaboration agreement with NYU Langone Health PME and NYU Langone Health to jointly develop next-generation enterprise imaging solutions PME to establish Research/R&D Hub in New York City New Hub to form the foundation for Visage research activities in the U.S. Significant investment in future PME products Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly- owned U.S. subsidiary, Visage Imaging, Inc., has signed a multi-year Research Collaboration agreement with NYU Langone Health (NYU Langone), one of the most highly regarded health systems in North America. Under the terms of the agreement, the two parties will work together to design and develop next-generation products for enterprise imaging in areas such as workflow optimization, integration with multi-vendor reporting platforms, as well as integration of artificial intelligence (AI) technology. NYU Langone will also become a member of the Visage AI Accelerator program. “This is a major milestone for our company,” said Dr Sam Hupert, Pro Medicus CEO. “We changed the paradigm of what a diagnostic imaging (PACS) product should be by natively integrating 3D and advanced visualisation into a single platform. We believe this, combined with our proprietary streaming platform, has given us an 18 to 24 month technology lead. We are now looking at what is next, what a system would look like in say 3 to 5 years, and are starting to do the research and development to make that a reality and then be the first to commercialise it.” In addition to working on-premise at NYU Langone, PME will establish its own R&D Hub in New York City to spearhead PME’s research and
11 September 2020; Company Announcement NYU Sept 2020 - Acrobat pdf 118k Highlights PME signs 7-year, A$25M deal with NYU Langone Health NYU Langone ranked in the 10 best hospitals by U.S. News & World Report 2020- 2021 Tier 1 academic institution which includes the renowned NYU Grossman School of Medicine Visage technology to be deployed throughout NYU’s imaging departments replacing systems from legacy vendors Extends PME’s footprint in the tier 1 U.S. academic hospital segment Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a 7-year contract with NYU Langone Health (NYU Langone), one of the largest health systems in the state of New York and one of the most respected and innovative healthcare institutions in North America. The contract, based on a transaction-based licensing model, will see the company’s Visage 7 technology implemented across all of NYU Langone’s radiology and subspecialty imaging departments, including breast imaging, replacing all existing legacy PACS with a single centralized instance of the Visage 7 Enterprise Imaging Platform. The implementation will span 6 hospitals and numerous additional locations across the NYU Langone healthcare network. Planning for the rollout is to commence in Q2 FY21, with the first sites scheduled to go-live in Q3 FY21. “NYU Langone completed a thorough selection process that required the final round of vendors to perform extensive on-site pilots. This enabled NYU to assess the differences between systems and, importantly, do so in their production environment, which is the ultimate test of how a product will perform,” said Dr Sam Hupert, Pro Medicus CEO. “Winning this deal further validates our belief that we have a unique and highly differentiated